What Is the Fair Value of Johnson & Johnson (JNJ) Stock? Intrinsic Value Analysis

Quick Answer

Based on a comprehensive intrinsic value analysis utilizing multiple valuation models in July 2026, Johnson & Johnson (JNJ) is currently overvalued.

While the company's underlying fundamentals remain robust—highlighted by a raised 2026 revenue guidance midpoint of $101.1 billion and strong oncology sales—the current stock price of $252 has outpaced its intrinsic value. Our blended fair value estimate for JNJ stock sits in the $190.00 to $199.00 range. At 21.6x forward earnings, the stock is trading at a significant premium to its historical averages, suggesting that investors are paying a steep price for the company's safety and recent earnings beats.

Current Stock Price & Valuation

As of mid-July 2026, Johnson & Johnson's market pricing reflects high expectations following a strong second-quarter earnings report.

The stock's current P/E of 21.6x is notably higher than the company's historical fair value multiple of 17.0x Johnson & Johnson (JNJ) - Sure Dividend. This multiple expansion is the primary driver of the stock's current overvaluation.

Detailed Analysis

To determine the true intrinsic value of JNJ, we must triangulate its valuation using five distinct methodologies.

1. Discounted Cash Flow (DCF) Analysis

The DCF model estimates the present value of JNJ's future free cash flows (FCF). In Q2 2026, JNJ generated approximately $8.7 billion in free cash flow Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson.

  • Inputs:
  • Calculation: Discounting the next five years of cash flows yields a present value of approximately $95 billion. Calculating the terminal value (assuming 2.5% perpetual growth discounted at 8.0%) and discounting it to the present adds roughly $380 billion. Adding cash of $20.4 billion jnj-20260628 and subtracting debt gives an implied equity value of ~$465 billion.
  • Implied Fair Value: $193.75 per share (assuming ~2.4 billion shares outstanding).

2. P/E Multiple Analysis

This relative valuation method compares JNJ's forward earnings against its historical trading multiples.

3. PEG Ratio Analysis

The Price/Earnings-to-Growth (PEG) ratio factors in the company's expected earnings growth rate to determine if the P/E ratio is justified.

  • Inputs:
  • Calculation: 21.6 / 6.0 = 3.6x PEG Ratio.
  • Analysis: A PEG ratio of 1.0 is traditionally considered fair value. A PEG of 3.6x indicates severe overvaluation relative to the company's mid-single-digit growth prospects. To achieve a more reasonable PEG of 2.0x to 2.5x (standard for wide-moat mega-caps), the stock would need to trade closer to $175.00.

4. EV/EBITDA Valuation

Enterprise Value to EBITDA provides a capital-structure-neutral view of the company's operating cash yield.

5. Dividend Discount Model (DDM)

Because JNJ is a legendary dividend payer with 64 consecutive years of dividend increases Johnson & Johnson (JNJ) - Sure Dividend, the DDM is highly relevant.

Bull Case

The bullish argument for JNJ centers on its exceptional operational execution in 2026. In Q2 2026, the Innovative Medicine unit grew 7.8% to $16.38 billion Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength. This was heavily driven by the blood cancer treatment Darzalex, which generated $4.2 billion in the quarter, and the immunology drug Tremfya, which surged 72.5% year-over-year to $2 billion Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength.

Furthermore, management's confidence is palpable. They raised 2026 guidance, projecting that annual revenue will cross the $100 billion mark for the first time in the company's 140-year history, landing at an estimated $101.1 billion Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson. Bulls argue that JNJ's wide economic moat and dominance in oncology justify a premium P/E multiple above 20x.

Bear Case

The bear case focuses heavily on valuation risk and looming patent cliffs. At $252, the stock is priced for perfection. If the P/E multiple compresses from its current 21.6x back to its historical average of 17.0x, investors could suffer a -4.7% annualized drag on returns through 2031 Johnson & Johnson (JNJ) - Sure Dividend.

Operationally, JNJ still faces the ongoing Stelara patent cliff headwind Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility | Morningstar. Additionally, the MedTech division is experiencing temporary weakness due to the narrowed use of Impella heart pumps, which will lack updated Protect-IV study data until 2027 Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility | Morningstar. If Innovative Medicine growth slows, there is little margin of safety at current prices.

Key Metrics Summary

MetricCurrent (July 2026)Target / Historical
Stock Price$252.00$190.00 - $199.00
Market Cap$606 BillionN/A
Forward P/E21.6x17.0x
Dividend Yield2.1%2.5% - 3.0%
2026 Revenue Guidance$101.1 BillionN/A
2026 Adj. EPS Guidance$11.68N/A
5-Year Growth Est.6.0%N/A

Frequently Asked Questions

Why did Johnson & Johnson raise its 2026 guidance?

JNJ raised its 2026 guidance following a strong Q2 where revenue grew 6.6% to $25.3 billion Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson. The outperformance was driven by massive market share gains in its oncology and immunology portfolios, specifically the drugs Darzalex and Tremfya Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility | Morningstar.

Is JNJ's dividend safe at current levels?

Yes, the dividend is exceptionally safe. In April 2025, JNJ increased its dividend for the 64th consecutive year Johnson & Johnson (JNJ) - Sure Dividend. The company generated ~$8.7 billion in free cash flow in Q2 2026 alone [Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson](https://investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook], easily covering its dividend obligations.

What do major research firms consider the fair value of JNJ?

Independent research firms align closely with our intrinsic value calculations. Morningstar currently maintains a fair value estimate of $190.00 per share Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility | Morningstar, while Sure Dividend calculates a fair value price of $199.00 Johnson & Johnson (JNJ) - Sure Dividend.

Final Verdict

Johnson & Johnson is a phenomenal, wide-moat business executing flawlessly, as evidenced by its path to $100+ billion in 2026 revenue. However, a great company is not always a great stock.

At $252 per share, JNJ is overvalued by approximately 25% to 30%. The current valuation requires a 21.6x earnings multiple, which leaves investors vulnerable to multiple compression. Based on DCF, P/E, and DDM models, the intrinsic fair value of JNJ stock is firmly in the $190.00 to $199.00 range. Value-conscious investors should wait for a broader market pullback to initiate or add to positions at a more favorable margin of safety.

Ready to Analyze Your Next Investment?

Get a free AI-powered fair value analysis on any stock. See intrinsic value, margin of safety, and institutional-grade risk metrics in seconds. No credit card required.

Want full access to our institutional research tools? Explore Invest Daily Pro.

Put This Into Practice

You're learning how to value stocks. Now apply it to any ticker in seconds.

Enter any ticker and our engine runs a DCF model, compares P/E to industry medians, and gives you an intrinsic value range with a margin of safety estimate.

Watch: Related Videos

from Invest Daily
Watch: I Built an AI That Values Any Stock in 30 Seconds (Full Demo)
YouTube
Watch: $3 TRILLION Gone in One Day… What Happens to Stocks This Week?
YouTube

Get This Analysis in Your Inbox Every Morning

Get our daily market briefing with institutional-grade analysis, key developments, and actionable strategy - delivered before the opening bell.